These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19852689)

  • 21. Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.
    Payne CD; Li YG; Brandt JT; Jakubowski JA; Small DS; Farid NA; Salazar DE; Winters KJ
    Platelets; 2008 Jun; 19(4):275-81. PubMed ID: 18569863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.
    Migliorini A; Valenti R; Marcucci R; Parodi G; Giuliani G; Buonamici P; Cerisano G; Carrabba N; Gensini GF; Abbate R; Antoniucci D
    Circulation; 2009 Dec; 120(22):2214-21. PubMed ID: 19917884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
    Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA
    J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions.
    Lepäntalo A; Virtanen KS; Heikkilä J; Wartiovaara U; Lassila R
    Eur Heart J; 2004 Mar; 25(6):476-83. PubMed ID: 15039127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
    Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX
    Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial.
    Yong G; Rankin J; Ferguson L; Thom J; French J; Brieger D; Chew DP; Dick R; Eccleston D; Hockings B; Walters D; Whelan A; Eikelboom JW
    Am Heart J; 2009 Jan; 157(1):60.e1-9. PubMed ID: 19081397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation.
    Siller-Matula JM; Haberl K; Prillinger K; Panzer S; Lang I; Jilma B
    Thromb Res; 2009 Apr; 123(6):874-80. PubMed ID: 19135705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Storey RF; Husted S; Harrington RA; Heptinstall S; Wilcox RG; Peters G; Wickens M; Emanuelsson H; Gurbel P; Grande P; Cannon CP
    J Am Coll Cardiol; 2007 Nov; 50(19):1852-6. PubMed ID: 17980251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
    Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA
    Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome.
    Lemesle G; Delhaye C; Sudre A; Broucqsault D; Rosey G; Bauters C; Lablanche JM
    Am Heart J; 2009 Feb; 157(2):375-82. PubMed ID: 19185648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial.
    Gurbel PA; Cummings CC; Bell CR; Alford AB; Meister AF; Serebruany VL;
    Am Heart J; 2003 Feb; 145(2):239-47. PubMed ID: 12595840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests.
    Shenkman B; Matetzky S; Fefer P; Hod H; Einav Y; Lubetsky A; Varon D; Savion N
    Thromb Res; 2008; 122(3):336-45. PubMed ID: 18155752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial.
    Montalescot G; Sideris G; Meuleman C; Bal-dit-Sollier C; Lellouche N; Steg PG; Slama M; Milleron O; Collet JP; Henry P; Beygui F; Drouet L;
    J Am Coll Cardiol; 2006 Sep; 48(5):931-8. PubMed ID: 16949482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Hernández-Antolín R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Macaya C
    J Invasive Cardiol; 2004 Jun; 16(6):325-9. PubMed ID: 15156004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention.
    Sibbing D; von Beckerath O; Schömig A; Kastrati A; von Beckerath N
    Am J Cardiol; 2007 Jul; 100(2):203-5. PubMed ID: 17631070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
    Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Carvajal J; Lehmann A; Lambert M; Bonnet JL; Alessi MC
    J Am Coll Cardiol; 2006 Oct; 48(7):1339-45. PubMed ID: 17010792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
    James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
    Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rash with both clopidogrel and ticlopidine in two patients following percutaneous coronary intervention with drug-eluting stents.
    Makkar K; Wilensky RL; Julien MB; Herrmann HC; Spinler SA
    Ann Pharmacother; 2006 Jun; 40(6):1204-7. PubMed ID: 16684808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
    J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
    Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM;
    Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.